Geron Corporation Announces Proposed Public Offering of Common Stock
January 04 2023 - 4:19PM
Business Wire
Geron Corporation (Nasdaq: GERN), a late-stage clinical
biopharmaceutical company, today announced that it intends to offer
and sell $175 million of shares of its common stock in an
underwritten public offering. All of the securities in the proposed
offering are to be sold by Geron. Geron intends to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the number of shares of its common stock offered in the public
offering. The proposed offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Goldman Sachs & Co. LLC and Stifel are acting as joint
book-running managers for the offering. Wedbush PacGrow and Baird
are acting as co-lead managers for the offering. B. Riley
Securities and Needham & Company are acting as co-managers for
the offering.
An automatically effective shelf registration statement on Form
S-3 relating to the public offering of the shares of common stock
described above was filed with the Securities and Exchange
Commission (SEC) on January 4, 2023. A preliminary prospectus
supplement and accompanying prospectus relating to and describing
the terms of the proposed offering will be filed with the SEC and
will be available for free on the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and
accompanying prospectus relating to the proposed offering may be
obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, New York 10282, by telephone
at 1-866-471-2526 or by email at prospectus-ny@ny.email.gs.com; and
Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate,
One Montgomery Street, Suite 3700, San Francisco, California 94104,
by telephone at 415-364-2720 or by email at
syndprospectus@stifel.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Geron
Geron is a late-stage biopharmaceutical company pursuing
therapies with the potential to extend and enrich the lives of
patients living with hematologic malignancies. Its investigational
first-in-class telomerase inhibitor, imetelstat, harnesses Nobel
Prize winning science in a treatment that may alter the underlying
course of these diseases.
Use of Forward-Looking Statements
Investors are cautioned that statements in this press release
regarding the intention, completion, timing and option relating to
the proposed public offering constitute forward-looking statements
that involve risks and uncertainties, including, without
limitation, risks and uncertainties related to: whether or not
Geron will be able to raise capital through the sale of its
securities; the final terms of the proposed offering, market and
other conditions; the satisfaction of customary closing conditions
related to the proposed public offering and the impact of general
economic, industry or political conditions in the United States or
internationally, the current or evolving effects of macroeconomic
conditions, such as the COVID-19 pandemic, civil or political
unrest or military conflicts around the world, such as the military
conflict between Ukraine and Russia, inflation, rising interest
rates or prospects of a recession, on Geron’s business operations
and activities. There can be no assurance that Geron will be able
to complete the proposed public offering on acceptable terms, or at
all. Actual results may differ materially from the results
anticipated in these forward-looking statements. Additional
information on other potential factors that could affect Geron’s
results and other risks and uncertainties can be found under the
heading “Risk Factors” or other similar headings found in documents
Geron files from time to time with the SEC, including Geron’s
quarterly report on Form 10-Q for the quarter ended September 30,
2022 and the preliminary prospectus supplement related to the
proposed offering to be filed with the SEC on or about the date
hereof. Geron expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230104005942/en/
Aron Feingold Investor and Media Relations investor@geron.com
media@geron.com
Geron (NASDAQ:GERN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Jul 2023 to Jul 2024